COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study

Background Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cardiovascular medicine Vol. 9; p. 998842
Main Authors Parenica, Jiri, Benesova, Klara, Radvan, Martin, Sanca, Ondrej, Hlasensky, Jiri, Lokaj, Petr, Ondrus, Tomas, Helanova, Katerina, Kala, Petr, Dusek, Ladislav, Jarkovsky, Jiri
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 20.10.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave. Methods Chronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment. Findings From a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group. Interpretation The results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Federica Moscucci, Sapienza University of Rome, Italy; Peter Klimek, Medical University of Vienna, Austria
This article was submitted to Heart Failure and Transplantation, a section of the journal Frontiers in Cardiovascular Medicine
Edited by: Elisabetta Salvioni, Monzino Cardiology Center (IRCCS), Italy
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2022.998842